CAMBRIDGE, Mass., Dec. 13, 2011 (GLOBE NEWSWIRE) -- Pathfinder Cell Therapy, Inc. ("Pathfinder") (OTCQB:PFND), a biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage, today provided a progress update on its research and development activities for the Company's proprietary Pathfinder Cells ("PCs"). In multiple animal models, Pathfinder has confirmed the ability of PCs to stimulate the natural regeneration of surrounding damaged tissues without the cells being incorporated into the newly generated tissue. These positive preliminary data support further development of PCs as a potential treatment for several important human diseases including diabetes, cardiac ischemia, and renal reperfusion injury.
